[go: up one dir, main page]

WO2006024283A3 - Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases - Google Patents

Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases Download PDF

Info

Publication number
WO2006024283A3
WO2006024283A3 PCT/DE2005/001527 DE2005001527W WO2006024283A3 WO 2006024283 A3 WO2006024283 A3 WO 2006024283A3 DE 2005001527 W DE2005001527 W DE 2005001527W WO 2006024283 A3 WO2006024283 A3 WO 2006024283A3
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic
methods
carcinoma
pancreatic carcinoma
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2005/001527
Other languages
German (de)
French (fr)
Other versions
WO2006024283A2 (en
Inventor
Guenter Kloeppel
Jutta Luettges
Holger Kalthoff
Ole Ammerpohl
Robert Gruetzmann
Christian Pilarsky
Hans-Detlev Saeger
Ingo Alldinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Dresden
Original Assignee
Technische Universitaet Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Dresden filed Critical Technische Universitaet Dresden
Priority to DE112005002742T priority Critical patent/DE112005002742B4/en
Publication of WO2006024283A2 publication Critical patent/WO2006024283A2/en
Publication of WO2006024283A3 publication Critical patent/WO2006024283A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods for the diagnosis and prognosis of pancreatic carcinoma, particularly of ductal adenoma carcinoma of the pancreas, to methods for screening for active substances for treating pancreatic carcinoma, and to the use of antisense construction or siRNA molecules for producing a pharmaceutical composition for treating pancreatic carcinoma. By performing comparative examination of the gene expression in the pancreatic carcinoma and in the normal pancreatic epithelial tissue, all in all, 1419 differentially expressed genes (650 up-regulated and 769 down-regulated genes) were found. Until now, it was unknown that 1267 of the found 1419 genes were correlated with pancreatic tumors. It can be established whether a pancreatic carcinoma exists by determining the amount of gene product of a differentially expressed gene of this type in a sample of biological origin of an individual and by comparing it with the amount of gene product present in the pancreatic tissue.
PCT/DE2005/001527 2004-08-31 2005-08-26 Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases Ceased WO2006024283A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112005002742T DE112005002742B4 (en) 2004-08-31 2005-08-26 Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200410042822 DE102004042822A1 (en) 2004-08-31 2004-08-31 Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases
DE102004042822.0 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006024283A2 WO2006024283A2 (en) 2006-03-09
WO2006024283A3 true WO2006024283A3 (en) 2006-08-31

Family

ID=35853531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2005/001527 Ceased WO2006024283A2 (en) 2004-08-31 2005-08-26 Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases

Country Status (2)

Country Link
DE (2) DE102004042822A1 (en)
WO (1) WO2006024283A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
KR102058996B1 (en) 2013-04-17 2019-12-24 엘지전자 주식회사 Biomarker for diagnossis of pancreatic cancer using target genes of microrna

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2052739A4 (en) * 2006-08-16 2010-01-06 Forerunner Pharma Res Co Ltd CANCER THERAPEUTIC AGENT COMPRISING A LIGAND FOR NEUROMEDIN U RECEPTOR 2 MOLECULE (FM4) AS ACTIVE INGREDIENT
EP2061900A2 (en) * 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
JP2010133705A (en) * 2007-03-16 2010-06-17 Perseus Proteomics Inc Diagnostic drug and curative medicine of cancer
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
JP2011505357A (en) 2007-12-03 2011-02-24 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア Oxysterols to activate hedgehog signaling, osteoinduction, anti-lipogenesis, and WNT signaling
DE102010043541B4 (en) 2009-12-16 2012-01-26 Technische Universität Dresden Method and means for predicting survival in pancreatic carcinoma by analysis of biomarkers
GB0922085D0 (en) * 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
WO2011151321A1 (en) * 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
EP2463657A1 (en) * 2010-12-13 2012-06-13 Université de Liège Biomarkers, uses of biomarkers and a method of identifying biomarkers
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
US9717742B2 (en) 2012-05-07 2017-08-01 The Regents Of The University Of California Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
WO2014186773A1 (en) * 2013-05-17 2014-11-20 National Health Research Institutes Methods of prognostically classifying and treating glandular cancers
EP3159695A3 (en) * 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Methods for diagnosing pancreatic cancer
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
JP6818348B2 (en) * 2016-12-27 2021-01-20 株式会社キュービクス Detection of cancer using cystatin A as a marker
CN113767289A (en) * 2019-05-08 2021-12-07 德国癌症研究公共权益基金会 Colorectal cancer screening and early detection method
CN110702923B (en) * 2019-11-05 2022-12-27 南通大学附属医院 Application of GPR115 gene in preparation of anti-lung cancer drugs and diagnostic kit thereof
CN111973744B (en) * 2020-07-15 2022-07-01 北京大学深圳医院 Application of PLCE1-AS2 in breast cancer
WO2023004460A1 (en) * 2021-07-28 2023-02-02 Hudson Institute of Medical Research Methods of detecting and/or diagnosing pancreatic cancer
WO2023133275A1 (en) * 2022-01-07 2023-07-13 Sanford Burnham Prebys Medical Discovery Institute Inhibition of glutaryl-coa dehydrogenase for the treatment of melanoma
CN114480399A (en) * 2022-03-17 2022-05-13 江苏医药职业学院 siRNA for reducing CPB1 gene expression, recombinant vector and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046369A2 (en) * 1999-02-02 2000-08-10 Chiron Corporation Polynucleotides related to pancreatic disease
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601826B2 (en) * 2002-09-30 2009-10-13 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046369A2 (en) * 1999-02-02 2000-08-10 Chiron Corporation Polynucleotides related to pancreatic disease
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRESS T M ET AL: "A pancreatic cancer-specific expression profile", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 13, 1996, pages 1819 - 1830, XP002089888, ISSN: 0950-9232 *
MAITRA A. ET AL.,: "global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays", CLIN. CANCER RESEARCH, vol. 9, December 2003 (2003-12-01), pages 5988 - 5995, XP002376207 *
RYU BYUNGWOO ET AL: "Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, no. 3, 1 February 2002 (2002-02-01), pages 819 - 826, XP002251739, ISSN: 0008-5472 *
VOZ M.L. ET AL.,: "microarray screening for target genes of the proto-oncogene plag1", ONCOGENE, vol. 23, 8 January 2004 (2004-01-08), pages 179 - 191, XP002376208 *
WERNER S R ET AL: "OVEREXPRESSION OF ONCOGENIC PRL TYROSINE PHOSPHATASES IN HUMAN BREAST, OVARIAN, ENDOMETRIAL, AND PANCREATIC CANCERS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 44, July 2003 (2003-07-01), pages 1000, XP008032686, ISSN: 0197-016X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
KR102058996B1 (en) 2013-04-17 2019-12-24 엘지전자 주식회사 Biomarker for diagnossis of pancreatic cancer using target genes of microrna

Also Published As

Publication number Publication date
DE112005002742B4 (en) 2008-05-21
DE102004042822A1 (en) 2006-03-16
DE112005002742A5 (en) 2007-08-09
WO2006024283A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
WO2006024283A3 (en) Compounds and methods for the treatment, diagnosis and prognosis of pancreatic diseases
Lee et al. A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation of Snail1
Liu et al. miR‐134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene
Yoo et al. miR-181b-3p promotes epithelial–mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG
Georgantas III et al. Micro RNA‐206 induces G 1 arrest in melanoma by inhibition of CDK 4 and C yclin D
Tay et al. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells
Chen et al. The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis
Liu et al. MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1
Mairinger et al. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study
Zhang et al. The long non-coding RNA MIAT regulates zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoteing cell invasion in non-small-cell lung cancer
Takei et al. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer
Tao et al. LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression
Chai et al. MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells
Cao et al. Overexpression of Chemokine (CXC) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma
Okada et al. Inhibition of micro RNA‐214 ameliorates hepatic fibrosis and tumor incidence in platelet‐derived growth factor C transgenic mice
Fang et al. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma
Lian et al. Anti-miRNA-23a oligonucleotide suppresses glioma cells growth by targeting apoptotic protease activating factor-1
Meng et al. MicroRNA-202 inhibits tumor progression by targeting LAMA1 in esophageal squamous cell carcinoma
Zhu et al. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia
WO2007085497A8 (en) Markers for the prediction of outcome of anthracycline treatment
Jin et al. FXR1 is elevated in colorectal cancer and acts as an oncogene
Luo et al. MicroRNA-432-5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer
Bartl et al. The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors
WO2008143774A2 (en) Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
Bernaldo de Quirós et al. Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22. 2 for migratory capacity in head and neck squamous cell carcinomas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1120050027422

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
REF Corresponds to

Ref document number: 112005002742

Country of ref document: DE

Date of ref document: 20070809

Kind code of ref document: P

122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8607

REG Reference to national code

Ref country code: DE

Ref legal event code: 8607